Shares of Osiris Therapeutics Inc. sank 21 percent after the firm reported problems with the design of an ongoing pivotal Phase III study of adult stem cell product Prochymal in Crohn's disease and halted the study only 60 patients away from the 270-subject enrollment goal. (BioWorld Today)